VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE INJECTION (SYH2069 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Hong Kong Exchanges and Clearing Limited and The Stock Excha nge of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoe ver for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this ann ouncement. CSPC PHARMACEUTICAL GROUP LIMITED (Incorporated in Hong Kong with limited liability) (Stock Code: 1093) ʮ ̡ VOLUNTARY ANNOUNCEMENT GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE INJEC TION (SYH2069 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHI NA The Board of Directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that GLP-1/GIP receptor dual- biased agonist polypeptide injection (SYH2069 Injection) (the ‘‘Product ’’) developed by the Group has obtained approval from the National Medical Products Admin istration of the People ’s Republic of China to conduct clinical trials in China. Previously, the P roduct has also obtained approval from the U.S. Food and Drug Administration to conduct clinical trial s in the U.S. With the potential to become China ’s first GLP-1/GIP receptor dual-biased agonist to enter cli nical development, the Product can selectively activate the cAMP pathway and markedly reduce b-arrestin recruitment, thereby decreasing receptor internalizatio n and desensitization, enhancing drug efficacy, and extending the durability of effect. Furthermore, throu gh the integration of long half-life modification platform technology, the Product can achieve more profound and sustained weight loss effects. In studies involving diet-induced obesity (DIO) m ice and non-human primates, the Product demonstrated significantly superior efficacy on weight lo ss and metabolic improvement compared to similar marketed products. Repeat-dose toxicology studie s in non-human primates indicated that the Product was well-tolerated, with no vomiting or gastrointe stinal adverse reactions observed. With its outstanding efficacy and good safety profile, the Product i s expected to become a new-generation therapeutic agent for overweight/obesity and other metabo lic diseases. – 1 – The indication for this clinical trial approval is weight ma nagement for individuals with obesity or overweight and at least one weight-related comorbidity. In addition, the Product also has the potential to improve glycemic control in adults with type 2 diabetes me llitus (T2DM), providing a promising clinical development value. By Order of the Board CSPC Pharmaceutical Group Limited CAI Dong Chen Chairman Hong Kong, 29 December 2025 As at the date of this announcement, the Board comprises Mr. C AI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiy u, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong, as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, M r. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors. – 2 –

The release as fetched from its publisher. irasia.com ↗